Expected to open the first BNCT Boron Neutron Capture Therapy Center in Hong Kong, China Life Science is eager to settle in the Hong Kong-Shenzhen Innovation Park

On April 18, China Biotech Services (08037) announced that it had signed a memorandum of understanding with Hong Kong-Shenzhen Innovation and Technology Park Limited (hereinafter referred to as "Hong Kong-Shenzhen Sci-Tech Park") and held a partnership launch ceremony at the Hong Kong-Shenzhen Sci-Tech Park.

According to the memorandum of understanding, Hong Kong-Shenzhen Sci-Tech Park plans to introduce the Boron Neutron Capture Therapy (BNCT) project. China Biotech Services will collaborate with Japan's Sumitomo Heavy Industries Machinery Co., Ltd. and Japanese boron drug company Stella Pharma Co., Ltd. to jointly build the BNCT Hetao Treatment Center in the Hetao area of Hong Kong.

Hong Kong-Shenzhen Sci-Tech Park is the Hong Kong area of the Hetao Hong Kong-Shenzhen Science and Technology Innovation Cooperation Zone. With its geographical advantages, it will become an important platform for cooperation with mainland China in science and technology innovation, helping to promote Hong Kong's integration into national development and benefiting partners of Hong Kong-Shenzhen Sci-Tech Park and the entire innovation community. The introduction of the Boron Neutron Capture Therapy project this time also reflects Hong Kong-Shenzhen Sci-Tech Park's optimism about the development prospects of this therapy.

According to the Securities Times app, China Biotech Services is steadily advancing its CAR-T business and the commercialization of the Boron Neutron Treatment Center as expected. The Pengbo Boron Neutron Hospital located in the Boao Lecheng International Medical Tourism Pioneer Zone has achieved full completion as planned in December 2023 and has begun installing equipment. It is expected to start operations and receive patients by the end of 2024 or early 2025.

The memorandum of understanding reached with Hong Kong-Shenzhen Sci-Tech Park Company signifies the specific manifestation of its accelerated commercialization process of the Boron Neutron Capture Therapy, marking China Biotech Services as the first enterprise to establish a Boron Neutron Capture Treatment Center in Hong Kong. This will lay the foundation for its future to serve cancer patients in Hong Kong, the Greater Bay Area, Southeast Asia, and South Asia based on its geographical advantages.

Meanwhile, China Biotech Services' subsidiary, Shanghai Longyao Biotechnology, is conducting clinical trials at Shanghai Ruijin Hospital and Jiangsu Provincial People's Hospital, and will announce the latest clinical research data on the targeted CD20 CAR-T product LY007 cell injection solution at the 2024 ASCO Annual Meeting.

In recent years, China Biotech Services has been committed to building an advanced biotechnology platform for integrated cancer diagnosis and treatment, with a focus on precision diagnosis, CAR-T cell therapy, and BNCT Boron Neutron Therapy. The company has already achieved regional or international leading advantages. With the accelerated development of the company's CAR-T business and the rapid commercialization of Boron Neutron Therapy, China Biotech Services is poised for a moment of value explosion